Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238060 | 1.00 | LMNA (0.46) | LMNAFOLH1CHIT1DPP4CA1 | |
| SCHEMBL436094 | 0.99 | LMNA (0.45) | LMNAFOLH1CHIT1DPP4CA1 | |
| SCHEMBL18118425 | 0.93 | LMNA (0.43) | LMNAFOLH1CHIT1DPP4CA1 | |
| SCHEMBL17119211 | 0.93 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL1079200 | 0.93 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL1996255 | 0.93 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL5864632 | 0.93 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL15904929 | 0.93 | FOLH1 (0.45) | FOLH1CHIT1DPP4CA1CA2 | |
| Hydrochloric Acid SCHEMBL31226505 | 0.91 | FOLH1 (0.44) | FOLH1CHIT1DPP4CA1CA2 | |
| SCHEMBL12261650 | 0.91 | FOLH1 (0.41) | LMNAFOLH1CHIT1DPP4SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610370-B2 | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-20140248213-A1 | COMPOSITIONS AND METHODS FOR TUMOR IMAGING AND TARGETING BY A CLASS OF ORGANIC HEPTAMETHINE CYANINE DYES THAT POSSESS DUAL NUCLEAR AND NEAR-INFRARED PROPERTIES | CEDARS-SINAI MEDICAL CENTER (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248213-A1 | COMPOSITIONS AND METHODS FOR TUMOR IMAGING AND TARGETING BY A CLASS OF ORGANIC HEPTAMETHINE CYANINE DYES THAT POSSESS DUAL NUCLEAR AND NEAR-INFRARED PROPERTIES | MKI67, HCCS, ARNT | LMNA 1486/4885FOLH1 862/4885CHIT1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.